Clinical Trial

Ultra-Safe Hormonal Strategy: Transdermal Estradiol Added to Progestins for Endometriosis

Study acronym: TAEDIUMVITAE
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated October 2, 2025 (before its estimated February 2026 completion). Its status may not reflect the trial's current state.
Summary
Endometriosis is a chronic, estrogen-dependent disease affecting women of reproductive age, associated with pelvic pain, infertility, and reduced quality of life. Progestins are the standard first-line therapy, but long-term treatment requires well-tolerated regimens that balance efficacy with patient satisfaction. This study will compare two combinations of progestins with natural transdermal estradiol-dienogest versus drospirenone-to evaluate which regimen provides greater patient satisfaction after 6 months of therapy.
Trial Details
NCT Number NCT07204093
Lead Sponsor Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Conditions Endometriosis
Enrollment 138 participants
Start Date 2025-08-11
Primary Completion 2026-02 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2025-10-02